1. Home
  2. LQDA vs NTCT Comparison

LQDA vs NTCT Comparison

Compare LQDA & NTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • NTCT
  • Stock Information
  • Founded
  • LQDA 2004
  • NTCT 1984
  • Country
  • LQDA United States
  • NTCT United States
  • Employees
  • LQDA N/A
  • NTCT N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • NTCT EDP Services
  • Sector
  • LQDA Health Care
  • NTCT Technology
  • Exchange
  • LQDA Nasdaq
  • NTCT Nasdaq
  • Market Cap
  • LQDA 1.9B
  • NTCT 1.6B
  • IPO Year
  • LQDA 2018
  • NTCT 1999
  • Fundamental
  • Price
  • LQDA $24.08
  • NTCT $26.44
  • Analyst Decision
  • LQDA Strong Buy
  • NTCT Buy
  • Analyst Count
  • LQDA 9
  • NTCT 2
  • Target Price
  • LQDA $32.67
  • NTCT $29.00
  • AVG Volume (30 Days)
  • LQDA 2.9M
  • NTCT 622.6K
  • Earning Date
  • LQDA 11-12-2025
  • NTCT 10-23-2025
  • Dividend Yield
  • LQDA N/A
  • NTCT N/A
  • EPS Growth
  • LQDA N/A
  • NTCT N/A
  • EPS
  • LQDA N/A
  • NTCT 1.02
  • Revenue
  • LQDA $19,322,000.00
  • NTCT $834,861,000.00
  • Revenue This Year
  • LQDA $405.58
  • NTCT $4.61
  • Revenue Next Year
  • LQDA $373.93
  • NTCT $2.80
  • P/E Ratio
  • LQDA N/A
  • NTCT $25.58
  • Revenue Growth
  • LQDA 30.20
  • NTCT 5.29
  • 52 Week Low
  • LQDA $9.71
  • NTCT $18.12
  • 52 Week High
  • LQDA $29.94
  • NTCT $27.89
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 52.50
  • NTCT 58.74
  • Support Level
  • LQDA $21.35
  • NTCT $25.46
  • Resistance Level
  • LQDA $23.33
  • NTCT $27.18
  • Average True Range (ATR)
  • LQDA 1.18
  • NTCT 0.49
  • MACD
  • LQDA 0.05
  • NTCT -0.06
  • Stochastic Oscillator
  • LQDA 83.30
  • NTCT 38.15

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About NTCT NetScout Systems Inc.

NetScout Systems Inc is a provider of service assurance and cybersecurity solutions to enterprise and government networks. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.

Share on Social Networks: